AGA Guideline on Surveillance of Barrett’s Esophagus

The American Gastroenterological Association (AGA) guideline on the surveillance of Barrett's Esophagus (BE) provides evidence-based recommendations aimed at improving early detection of dysplasia and reducing the risk of esophageal adenocarcinoma (EAC). Below is a detailed overview of the guideline's key aspects:

1. Purpose of the Guideline

The primary goal of the AGA guideline is to provide clinicians and patients with clear, evidence-based recommendations for endoscopic surveillance in Barrett’s Esophagus. This surveillance is intended to detect early neoplasia and reduce mortality associated with EAC.

2. Main Objective

The guideline seeks to answer critical questions about when and how surveillance should be performed, ensuring optimal outcomes for patients with BE. It emphasizes early detection of dysplasia or carcinoma while balancing risks, benefits, and feasibility.

3. Evidence Framework

The recommendations are developed using the GRADE methodology, which evaluates the quality of evidence, balances benefits against harms, incorporates patient values, and considers feasibility in clinical practice.

---

4. Key Recommendations

The guideline addresses various aspects of BE surveillance, including frequency, imaging techniques, sampling protocols, biomarkers, and chemoprevention. Below are the major recommendations:

Surveillance Frequency

• Nondysplastic Barrett's Esophagus (NDBE): AGA conditionally recommends surveillance endoscopy every 3 years for most patients with NDBE to detect early dysplasia or carcinoma.
• Low-Risk Patients: For patients with short-segment BE (<3 cm) and low risk of progression, surveillance intervals can be extended up to 5 years.
• Discontinuation of Surveillance: Surveillance should be stopped in patients with advanced age, significant comorbidities, or limited life expectancy. This is typically discussed around age 75.

Columnar-Lined Esophagus <1 cm

• Surveillance is not recommended for BE segments under 1 cm with intestinal metaplasia due to the extremely low risk of progression to cancer.

---

5. Imaging Strategy

• High-Definition White-Light Endoscopy (WLE) + Chromoendoscopy (CE):

AGA strongly recommends combining high-definition WLE with CE for better dysplasia detection compared to WLE alone.

• Choice of Chromoendoscopy: Either dye-based CE or virtual CE can be used, depending on the endoscopist's expertise and the available technology.

---

6. Sampling Technique

• A structured biopsy protocol is advised:
• Targeted biopsies from visible lesions.
• Four-quadrant random biopsies every 2 cm (or every 1 cm if there is a history of dysplasia).

Use of WATS-3D

• The guideline does not make a recommendation for or against WATS-3D adjunctive sampling due to insufficient evidence, highlighting this as a research gap.

---

7. Role of Biomarkers

• Routine biomarker testing (such as p53 or TissueCypher) is not recommended. Current evidence is limited and inconsistent, making their role in clinical practice unclear.

---

8. Chemopreventive Therapy

• Proton Pump Inhibitors (PPIs): Daily PPI therapy is conditionally recommended for BE patients to reduce the risk of neoplastic progression.
• PPIs vs. Antireflux Surgery: PPIs are preferred over antireflux surgery for preventing high-grade dysplasia or EAC due to better safety and comparable efficacy.

---

9. Quality Standards for Endoscopy

• Surveillance endoscopy should be performed using high-quality examinations by trained specialists to ensure accurate detection of dysplasia or early neoplasia.

---

10. Expert Pathology Confirmation

• Diagnoses of dysplasia or early EAC must be confirmed by an expert gastrointestinal pathologist to avoid misclassification, which can lead to inappropriate management.

---

11. Patient-Centered Approach

• Shared decision-making between clinicians and patients is emphasized. Surveillance intensity should align with individual risks, preferences, and values.

---

12. Safety of Endoscopy

• Surveillance endoscopy is considered safe, with very low complication rates. Serious adverse events such as bleeding or perforation occur in fewer than 1 in 10,000 cases.

---

13. Research Gaps and Future Focus

The guideline identifies several areas requiring further study to optimize BE management:

• Biomarkers: Research is needed to validate biomarkers for risk stratification.
• Nonendoscopic Screening Tools: Developing tools like capsule-sponge tests for easier and less invasive screening.
• Surveillance Intervals: Better-defined intervals for endoscopic surveillance based on individual risk factors.

---

Conclusion

The AGA guideline provides a comprehensive framework for the surveillance of Barrett's Esophagus, emphasizing evidence-based practices to improve early detection and outcomes while minimizing unnecessary interventions. It highlights the importance of personalized care, expert pathology review, and high-quality endoscopic techniques. Further research is required to address gaps in knowledge, particularly regarding biomarkers and nonendoscopic screening methods.